Open AccessMolidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Author(s) -
Hiroyasu Yamamoto,
Kiyoshi Nobori,
Yoshinobu Matsuda,
Yasuhiko Hayashi,
Takanori Hayasaki,
Tadao Akizawa
Publication year - 2021
Publication title -
american journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000518072
Subject(s) - medicine , darbepoetin alfa , anemia , erythropoietin , kidney disease , dialysis , adverse effect , randomized controlled trial , erythropoiesis , hemoglobin , surgery , urology , gastroenterology
Erythropoiesis-stimulating agents (ESAs) are the current standard of care for anemia due to chronic kidney disease (CKD) in patients not undergoing dialysis. Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being investigated as an alternative treatment for renal anemia. Molidustat was evaluated in five phase 3 studies, the molidustat once daily improves renal anemia by inducing erythropoietin (MIYABI) program. The present study investigated the safety and efficacy of molidustat in Japanese patients with renal anemia not undergoing dialysis and previously treated with ESAs.